Acute myocardial infarction (AMI) is a leading global cause of mortality. Conducting thorough risk assessments for chest pain patients and minimizing unfavorable outcomes can reduce morbidity, mortality, improve patient quality of life, and lower healthcare costs in various nations. In contemporary cardiology, multiple biomarkers are employed for diagnosis of myocardial infarction. Biomarkers play a pivotal role in the diagnosis and management of acute myocardial infarction (AMI). They are measurable indicators that provide valuable information about the presence, extent, and severity of cardiac injury. Commonly used biomarkers in AMI include cardiac troponins, creatine kinase-MB (CK-MB), and myoglobin. These biomarkers assist in the early diagnosis, risk stratification, and monitoring of AMI patients, ultimately aiding in timely and effective medical intervention to improve patient outcomes. Given the critical importance of timely detection and diagnosis in enhancing survival rates for acute myocardial infarction, cardiac biomarkers play a significant role in the prompt diagnosis of such cases.

Acute myocardial infarction (AMI) is a leading global cause of mortality.